MedGuideline Insider

The standard 3-step approach to treating hyperkalemia (elevated serum potassium, typically >5.5 mEq/L, with urgency increasing above 6.0–6.5 mEq/L or with ECG changes) focuses on:

1. Stabilizing the cardiac membrane (protect the heart).
2. Shifting potassium intracellularly (temporarily lower serum levels).
3. Eliminating potassium from the body (definitive removal). 

These steps are often addressed simultaneously in severe cases, alongside stopping all potassium intake/sources (supplements, IV fluids with K+, certain meds like ACEi/ARBs, spironolactone, NSAIDs, etc.) and addressing reversible causes (e.g., AKI, acidosis, rhabdomyolysis). Treatment is guided by severity, ECG findings (peaked T waves, widened QRS, etc.), symptoms, and kidney function. Always monitor ECG, repeat labs, and involve specialists (e.g., nephrology) as needed. 
Step 1: Membrane Stabilization (Protect the Heart)
• Primary agent: Intravenous calcium (does not lower K+ but antagonizes its cardiac effects).
• Calcium gluconate: Preferred in peripheral IV — 10 mL of 10% solution (1 g) over 2–5 minutes. Can repeat if ECG changes persist (after 5–10 min).
• Calcium chloride: 1 g (10 mL of 10%) over 2–5 minutes via central line (more irritating).
• Onset: 1–3 minutes; duration ~30–60 minutes.
• Indications: ECG changes, K+ >6.5–7 mEq/L, or symptomatic (arrhythmias, muscle weakness). Use even if ECG is normal in very severe cases. 
• Cautions: Avoid in digoxin toxicity (can worsen). Monitor for hypercalcemia.
This is the first priority in life-threatening hyperkalemia. 

Step 2: Shift Potassium Intracellularly (Temporary Redistribution)
This rapidly lowers serum K+ by driving it into cells (effects last 4–6 hours; rebound possible).
• Insulin + Glucose (most reliable):
• Regular insulin: 10 units IV bolus.
• With ~25–50 g dextrose (e.g., 1 amp D50W or D10W infusion) to prevent hypoglycemia.
• Onset: 15–30 min; peak 30–60 min; duration 4–6 hours.
• Monitor glucose hourly.
• Beta-2 agonists (add-on or alternative):
• Nebulized albuterol: 10–20 mg (higher dose than for asthma).
• Or subcutaneous terbutaline.
• Onset: ~30 min; additive to insulin.
• Other options (less routine):
• Sodium bicarbonate (if metabolic acidosis): 50–100 mEq IV.
• Avoid routine use without acidosis due to limited evidence and risks. 
Re-check K+ in 1–2 hours. These are bridging measures.

Step 3: Potassium Elimination/Removal (Definitive Therapy)
• Loop diuretics (e.g., furosemide 40–80 mg IV): If adequate urine output and eGFR >30–45; promotes urinary K+ excretion. Combine with IV fluids if volume-depleted (but avoid fluid overload). 
• Potassium binders:
• Newer agents preferred: Sodium zirconium cyclosilicate (SZC/Lokelma) or patiromer (Veltassa) — faster and better tolerated.
• Older: Sodium polystyrene sulfonate (Kayexalate) — slower, more GI side effects; use cautiously.

• Dialysis (hemodialysis): Most effective for rapid removal, especially in severe cases (K+ >6.5–7 with poor response, kidney failure, volume overload, or refractory hyperkalemia). Arrange urgently if needed.


• Other: Treat underlying issues (e.g., correct acidosis, stop offending drugs, manage constipation).

Monitoring & Follow-up: Continuous ECG, serial K+ levels (q1–2h initially), glucose, renal function. Hospitalize severe cases. For chronic/outpatient management, focus on diet (limit high-bioavailable K+ sources), meds optimization, and binders. 

Post 1:

Biomarker to diagnose Alzheimer disease
🧪Plasma P-Tau 217

Similar sensitivity like that of CSF examination and MRI brain 🧠.

🧠 Step 2 CK High-Yield Interpretation

1. LDL = Primary Treatment Target
• Drives atherosclerosis → CAD, stroke
• Statin therapy decisions based on LDL + ASCVD risk

⸻

2. Triglycerides
• 500 mg/dL → risk of pancreatitis
• Treat with:
• Fibrates
• Omega-3 fatty acids

⸻

3. HDL
• Low HDL = risk factor
• Increased by:
• Exercise
• Moderate alcohol

⸻

📅 Screening (USPSTF-oriented)
• Start:
• Men ≥35
• Women ≥45
• Earlier if risk factors:
• Diabetes
• Hypertension
• Smoking
• Obesity
• Family history

⸻

💊 Statin Indications (VERY HIGH-YIELD)

Treat regardless of baseline LDL in:
1. Clinical ASCVD
2. LDL ≥190 mg/dL
3. Age 40–75 + Diabetes Mellitus
4. Age 40–75 + elevated 10-year ASCVD risk (≥7.5%)

⸻

⚠️ Fasting vs Non-fasting
• Non-fasting is acceptable (current standard)
• Fasting needed if:
• TG > 400
• Suspected hypertriglyceridemia

⸻

🔑 Exam Traps
• Normal LDL but high TG → pancreatitis risk
• Diabetic patient → statin even if LDL normal
• LDL ≥190 → high-intensity statin immediately

⸻

H.Pylori Regimen:

Bismuth-Based Quadruple Therapy (First-line in many regions)

Duration: 14 days (preferred)
• Proton Pump Inhibitor (PPI)
• e.g., Omeprazole 20 mg BID
(Equivalent doses: Esomeprazole 20 mg BID, Lansoprazole 30 mg BID, Pantoprazole 40 mg BID)
• Bismuth Subsalicylate 524 mg QID
(or Bismuth Subcitrate 120–300 mg QID depending on formulation)
• Tetracycline 500 mg QID
• Metronidazole 500 mg TID–QID
(Higher frequency often used to overcome resistance)

🔬 Emerging Therapy for Acute PSVT Management: Etrapamil

Etrapamil, an intranasal non-dihydropyridine calcium channel blocker, is under clinical investigation for the acute conversion of Paroxysmal supraventricular tachycardia (PSVT).

Key potential advantages:
• Rapid systemic absorption via nasal mucosa
• Self-administration at symptom onset
• Reduction in emergency department utilization
• Avoidance of IV access

If Phase III data continue to demonstrate favorable safety and efficacy profiles, etrapamil may represent a paradigm shift in outpatient arrhythmia management.

Ongoing studies will clarify durability of conversion, recurrence rates, and hemodynamic tolerability.

Community Acquired Pneumonia requires Symptoms + pulmonary infiltrate on cxr to diagnose.
But sometimes pulmonary infiltrate might be missing in some cases . For eg in immunocompromised patients, patient on steroids etc unable to generate a strong cytokine response to recruit significant inflammatory cells to areas of pulmonary infection which results in minimal or no alveolar infiltrate on initial chest xray .

What to do next ?
If you have high suspicion , go for CT CHEST.

MRI breast indications:

🚨 Major Updates in Acute Ischemic Stroke Management (2026 Guidelines) 🚨

The newest stroke guidelines bring BIG changes — focusing on faster treatment, broader eligibility for reperfusion therapies, and smarter systems of care. Here are the key takeaways 👇

🧠 1. Systems of Care & Prehospital
• 🚑 Mobile Stroke Units now strongly recommended — faster thrombolysis = better outcomes
• 🏥 EMS should prioritize direct transport to thrombectomy-capable centers when LVO suspected
• 📊 Stronger emphasis on quality improvement, registries, and reducing transfer delays

💉 2. Thrombolysis (IVT) Updates
• ⭐ Tenecteplase (single bolus) endorsed as preferred alternative to alteplase
• ⏱️ Treatment window extended up to 9 hours (selected patients with advanced imaging)
• ⚡ Treat disabling deficits immediately — don’t delay for imaging inside 4.5 hours
• ❌ No thrombolysis for minor/nondisabling stroke (NIHSS ≤5) → use DAPT instead
• 🚫 No routine adjunct anticoagulants with IVT

🧬 3. Endovascular Thrombectomy (EVT) — Expanded Eligibility
• Larger infarct cores now eligible in selected patients
• 🔴 Basilar artery occlusion → strong recommendation within 24 hours
• 🧩 Selected M2 occlusions and mild prestroke disability included
• ✅ Give IVT + EVT when both indicated — don’t delay

👶 4. First Pediatric Stroke Recommendations
• MRI preferred imaging (CT if delay)
• IV thrombolysis may be considered in children with disabling deficits
• EVT reasonable in ≥6 years with LVO at experienced centers

🏥 5. Supportive Care Changes
• 🍬 Avoid intensive glucose control — treat only if >180 mg/dL
• 🩺 Avoid aggressive BP lowering after reperfusion (

3% Hypertonic Saline vs Mannitol in Severe TBI

3% hypertonic saline is at least as effective as mannitol in acutely decreasing ICP, with evidence supporting a more sustained effect and improved CPP in adults with severe TBI.

HTS may also provide superior intraoperative brain relaxation in craniotomy patients.

For pediatric patients, both agents are similarly effective.

The choice between HTS and mannitol should be individualized, taking into account patient-specific factors, clinical context, and institutional protocols.

💊ARBs of choice in different health conditions

🫀Chronic Kidney Disease (CKD)/Proteinuria: All are effective, but telmisartan, irbesartan, and losartan have strong supporting evidence.

🫀Metabolic Syndrome/Diabetes: Telmisartan is preferred due to metabolic benefits (improved insulin sensitivity).

🫀Stroke Prevention: Losartan (via LIFE study).

🫀Heart Failure: Valsartan or Candesartan.

🫀Hyperuricemia/Gout: Losartan.